TY - JOUR
T1 - Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma
T2 - A study on environmental malignant mesothelioma cases from Turkish villages
AU - Gümürdülü, Derya
AU - Zeren, E. Handan
AU - Cagle, Philip T.
AU - Kayaselçuk, Fazilet
AU - Alparslan, Nazan
AU - Kocabaş, Ali
AU - Tuncer, Ilhan
PY - 2002
Y1 - 2002
N2 - Histological diagnosis of malignant mesothelioma (MM) and differentiation from adenocarcinoma is often difficult. A number of clinical, radiologic, histologic and histochemical criteria have been used as diagnostic aids, but most cases cannot be readily classified on the basis of these characteristics. In recent years, a panel of immunohistochemical antibodies have been increasingly applied for the differential diagnosis of these two tumors. MOC-31 has been recently used as specific for adenocarcinomas while reacting with a minimal number of benign and malignant mesothelial proliferations, and HBME-1 has also been presented as a mesothelial cell marker. In this study, we aimed to show the importance of these two antibodies among the environmental MM cases from Southeastern Turkey. Fifty five cases of MM and twenty adenocarcinomas were included in this study. Histochemical (PAS, PAS-D, mucicarmine) and immunohistochemical (Keratin, EMA, CEA, MOC-31, HBME-1) stains have been performed on each case. Keratin was positive in all cases. EMA stained 50 of 55 MM and all the adenocarcinoma cases. According to our results, dPAS, mucicarmen, CEA and MOC-31 positivity was statistically significant in the diagnosis of adenocarcinoma whereas HBME-1 was demonstrable in most MM cases (52/55) and 11 adenocarcinoma cases. - This study confirmed that in the diagnostic distinction between MM and adenocarcinoma, immunohistochemistry is an important diagnostic tool, however, a panel of antibodies must be used rather than any single antibody. HBME-1 should be included in this panel; MOC-31 can be used where CEA is not available or to doublecheck the reactivity of this antibody.
AB - Histological diagnosis of malignant mesothelioma (MM) and differentiation from adenocarcinoma is often difficult. A number of clinical, radiologic, histologic and histochemical criteria have been used as diagnostic aids, but most cases cannot be readily classified on the basis of these characteristics. In recent years, a panel of immunohistochemical antibodies have been increasingly applied for the differential diagnosis of these two tumors. MOC-31 has been recently used as specific for adenocarcinomas while reacting with a minimal number of benign and malignant mesothelial proliferations, and HBME-1 has also been presented as a mesothelial cell marker. In this study, we aimed to show the importance of these two antibodies among the environmental MM cases from Southeastern Turkey. Fifty five cases of MM and twenty adenocarcinomas were included in this study. Histochemical (PAS, PAS-D, mucicarmine) and immunohistochemical (Keratin, EMA, CEA, MOC-31, HBME-1) stains have been performed on each case. Keratin was positive in all cases. EMA stained 50 of 55 MM and all the adenocarcinoma cases. According to our results, dPAS, mucicarmen, CEA and MOC-31 positivity was statistically significant in the diagnosis of adenocarcinoma whereas HBME-1 was demonstrable in most MM cases (52/55) and 11 adenocarcinoma cases. - This study confirmed that in the diagnostic distinction between MM and adenocarcinoma, immunohistochemistry is an important diagnostic tool, however, a panel of antibodies must be used rather than any single antibody. HBME-1 should be included in this panel; MOC-31 can be used where CEA is not available or to doublecheck the reactivity of this antibody.
KW - Adenocarcinoma
KW - Environmental malignant mesothelioma
KW - HBME-1
KW - MOC-31
KW - Turkey
UR - http://www.scopus.com/inward/record.url?scp=0036444604&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036444604&partnerID=8YFLogxK
U2 - 10.1007/BF03032393
DO - 10.1007/BF03032393
M3 - Article
C2 - 12515999
AN - SCOPUS:0036444604
SN - 1219-4956
VL - 8
SP - 188
EP - 193
JO - Pathology and Oncology Research
JF - Pathology and Oncology Research
IS - 3
ER -